Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2006-07-18
2006-07-18
Fredman, Jeffrey (Department: 1637)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C435S006120, C435S440000, C435S443000, C435S444000, C435S455000, C435S471000
Reexamination Certificate
active
07078389
ABSTRACT:
A mutagenic, triplex-forming oligonucleotide and methods for use thereof wherein the oligonucleotide is chemically modified to incorporate a mutagen and forms a triple-stranded nucleic acid molecule with a specific DNA segment of a target DNA molecule. Upon formation of the triplex, the mutagen is brought into proximity with the target molecule and causes a mutation at a specific site therein. The mutation activates, inactivates or alters the activity and function of the target molecule.
REFERENCES:
patent: 6303376 (2001-10-01), Glazer
patent: 0 226 099 (1988-05-01), None
patent: 0 375 408 (1990-06-01), None
Puri et al, “Targeted gene knockout by 2′-O-aminoethyl modified triplex forming oligonucleotides”, J. Biol. Chem. (2001) 276(31):28991-28998.
Lin et al, “Stability of DNA triplexes on shuttle vector plasmids in the replication pool in Mammalian cells”, J. Biol. Chem. (2000) 275(50):39117-39124.
Beal, et al., “Second Structural Motif for Recognition of DNA by Oligonucleotide-Directed Triple-Helix Formation,”Science251:1360-1363 (1991).
Beal, et al., “The Influence of Single Base Triplet Changes on the Stability of Pur-Pur-Pyr Triple Helix Determined by Affinity Cleaving,”Nuc. Acids Res. 11:2773 (1992).
Blume, et al., “Triple Helix Formation by Purine-Rich Oligonucleotides Targeted to the Human Dihydrofolate Reductase Promoter,”Nucleic Acids Rec. 20:1777 (1992).
Cooney, “Site-Specific Oligonucleotide Binding Represses Transcription of the Humanc-mycGene in Vitro,”Science241:456 (1998).
Durland, “Binding of Triple Helix Forming Oligonucleotides to Sites in Gene Promoters,”Biochemistry30:9246 (1991).
Duval-Valentin, et al., “Specific Inhibition of Transcription by Triple-Helix-Forming Oligonucleotides,”Proc. Natl. Acad. Sci. USA89:504 (1992).
Francois, “Sequence-Specific Recognition and Cleavage of Duplex DNA via Triple-Helix Formation by Oligonucleotides Covalently Linked to a Phenanthroline-Copper Chelate,”Proc. Natl. Acad. Sci. USA86:9702 (1989).
Gasparro, et al., “Site-specific targeting of Psoralen Photoadducts with a Triple Helix-Forming Oligonucleotide: Characterization of Psoralen Monoadduct and Crosslink Formation,”Nucleic Acids Research, 22(14):2845-2852 (1994).
Giovannangeli, et al., “Oligodeoxynucleotide-directed photo-induced cross-linking of HIV proviral DNA via triple-helix formation,”Nucleic Acids Res. 20:4275-4281 (1992).
Glazer, et al., “Detection and Analysis of UV-induced Mutations in Mammalian Cell DNA Using A Phage Suttle Vector,”Proc. Natl. Acad. Sci. 83:1041-1044 (1986).
Grigoriev, et al., “A Triple-Helix-Forming Oligonucleotide-Intercalator Conjugate Acts as a Transcriptional Repressor via Inhibition of NFkB Binding to Interleukin-2 Receptor α-Regulatory Sequence,”J. of Biological Chem. 267:3389 (1992).
Grigoriev, et al., “Inhibition of Gene Expression by Triple Helix-directed DNA Cross-linking at Specific Sites,”Proceedings of the National Academy of Sciences of USA, 90(8):3501-3505 (1993).
Havre, et al., “Targed Mutagenesis of DNA Using Triple Helix-forming Oligonucleotides Linked to Psoralen,”Proc. Natl. Acad. Sci. USA, 90(16):7879-7883 (1993).
Ito, et al., “Sequence-Specific DNA Purification by Triplex Affinity Capture,”Proc. Natl. Acad. Sci. USA89:495 (1992).
Lin, et al., “Use of EDTA Derivatization to Characterize Interactions Between Oligodeoxyribonucleoside Methylphosphonates and Nucleic Acids,”Biochemistry28:1054 (1989).
Maher, et al., “Analysis of Promoter-Specific Repression by Triple Helical DNA Complexes in a Eukarvotic Cell-Free Transcription System,”Biochemistry31:70 (1992).
Maher, et al.,Science245:725 (1989).
Mergny, et al., “Sequence Specificity in Triple-Helix Formation: Experimental and Theoretical Studies of the Effect of Mismatches on Triplex Stability,”Biochemistry30:9791 (1991).
Mirabelli, et al., “In Vitro and in vivo pharmacologic activities of antisense oligonucleotides,”Anticancer Design6:647-661 (1991).
Moser, et al., “Sequence-Specific Cleavage of Double Helical DNA by Triple Helix Formation,”Science238:645 (1987).
Orson, et al., “Oligonucleotide Inhibition of IL2Rα mRNA Transcription by Promoter Region Collinear Triplexed Formation in Lymphocytes,”Nucleic Acids Res. 19:3435 (1991).
Pei, “Site Specific Cleavage of Duplex DNA by a Semisynthetic Nuclease via Triple-Helix Formation,”Proc. Natl. Acad. Sci. USA87:9858 (1990).
Perrouault, et al., “Sequence-Specific Artificial Photo-induced Endonuclease Based on Triple Helix-Forming Oligonucleotides,”Nature344:358 (1990).
Postel, et al., “Evidence that a Triple-Forming Oligodeoxyibonucleotide Binds to thec-mycPromoter in HeLa Cells, Thereby Reducingc-mycmRNA Levels,”Proc. Natl. Acad. Sci. USA88-8227 (1991).
Posvic, et al., “Sequence-Specific Ikylation of Double Helical DNA by Oligonucleotide Directed Triple-Helix Formation,”J. Am. Chem. Soc. 112:9428 (1992).
Praseuth, et al., “Sequence-Specific Binding and Photocrosslinking of a α and β Oligodeoxynucleotides to the Major Groove of DNA via Triple-Helix Formation,”Proc. Natl. Acad. Sci. USA85:1349 (1988).
Strobel, “Site-Specific Cleavage of Human Chromosome 4 Mediated by Triple-Helix Formation,”Science254:1639 (1991).
Takasugi, et al., “Sequence-specific Photo-Induced Cross-Linking of the Two Strands of Double-Helical DNA by a Psoralen Covalently Linked to a Triple Helix Forming Oligonucleotide,”Proceedings of the National Academy of Sciences of USA88(13:5602-5606 (1991).
Uhlman, et al., “Antisense Oligonucleotides: A New Therapeutic Principle,”Chem. Reviews90(4):544-584 (1990).
Wood, et al., “The Effect of Volume and Temperature on the Energy and Entropy of Pure Liquids,”J. Am. Chem. Soc. 79:2023 (1957).
Young, “Triple Helix Formation Inhibits Transcription Elongationin vitro,” Proc. Natl. Sci. USA88:10023 (1991).
Glazer Peter M.
Havre Pamela A.
Fredman Jeffrey
Pabst Patent Group LLP
Yale University
LandOfFree
Chemically modified oligonucleotide for site-directed... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Chemically modified oligonucleotide for site-directed..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Chemically modified oligonucleotide for site-directed... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3530453